Noha N Salama

List of Publications by Year
in descending order

31	1,486	331259	433756
papers	citations	21 h-index	31 g-index

31	31	31	1985
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Targeting E-selectin to Tackle Cancer Using Uproleselan. Cancers, 2021, 13, 335.	1.7	30
2	Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma. Nature Communications, 2020, 11, 6037.	5.8	51
3	Targeting CD47 as a Novel Immunotherapy for Multiple Myeloma. Cancers, 2020, 12, 305.	1.7	56
4	Single dose oral ranolazine pharmacokinetics in patients receiving maintenance hemodialysis. Renal Failure, 2019, 41, 118-125.	0.8	3
5	Injectable Hydrogels for Localized Chemotherapy and Radiotherapy in Brain Tumors. Journal of Pharmaceutical Sciences, 2018, 107, 922-933.	1.6	35
6	Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma. Journal of Controlled Release, 2018, 270, 158-176.	4.8	49
7	Pazopanib plus cetuximab in recurrent or metastatic head and neck squamous cell carcinoma: an open-label, phase 1b and expansion study. Lancet Oncology, The, 2018, 19, 1082-1093.	5.1	21
8	Tariquidar sensitizes multiple myeloma cells to proteasome inhibitors via reduction of hypoxia-induced P-gp-mediated drug resistance. Leukemia and Lymphoma, 2017, 58, 2916-2925.	0.6	30
9	MEK inhibitor, TAK-733 reduces proliferation, affects cell cycle and apoptosis, and synergizes with other targeted therapies in multiple myeloma. Blood Cancer Journal, 2016, 6, e399-e399.	2.8	19
10	Newly established myeloma-derived stromal cell line MSP-1 supports multiple myeloma proliferation, migration, and adhesion and induces drug resistance more than normal-derived stroma. Haematologica, 2016, 101, e307-e311.	1.7	11
11	The role of P-glycoprotein in drug resistance in multiple myeloma. Leukemia and Lymphoma, 2015, 56, 26-33.	0.6	81
12	Buparlisib (NVP-BKM-120). Drugs of the Future, 2013, 38, 73.	0.0	3
13	Daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysis. Critical Care Medicine, 2011, 39, 19-25.	0.4	89
14	Longitudinal Hemodiafilter Performance in Modeled Continuous Renal Replacement Therapy. Blood Purification, 2011, 32, 82-88.	0.9	23
15	Single-dose daptomycin pharmacokinetics in chronic haemodialysis patients. Nephrology Dialysis Transplantation, 2010, 25, 1279-1284.	0.4	44
16	Etanercept Clearance during an in vitro Model of Continuous Venovenous Hemofiltration. Blood Purification, 2009, 28, 348-353.	0.9	2
17	Intradialytic Administration of Daptomycin in End Stage Renal Disease Patients on Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1190-1194.	2.2	40
18	Combining Drug and Immune Therapy: A Potential Solution to Drug Resistance and Challenges of HIV Vaccines?. Current HIV Research, 2008, 6, 401-410.	0.2	4

#	Article	IF	Citations
19	Enaminones: Exploring Additional Therapeutic Activities. Journal of Pharmaceutical Sciences, 2007, 96, 2509-2531.	1.6	77
20	Tight junction modulation and its relationship to drug deliveryâ˜†. Advanced Drug Delivery Reviews, 2006, 58, 15-28.	6.6	323
21	MDR1 haplotypes significantly minimize intracellular uptake and transcellular Pâ€gp substrate transport in recombinant LLCâ€PK1 cells. Journal of Pharmaceutical Sciences, 2006, 95, 2293-2308.	1.6	130
22	The Impact of Pharmacologic and Genetic Knockout of P-Glycoprotein on Nelfinavir Levels in the Brain and Other Tissues in Mice. Journal of Pharmaceutical Sciences, 2005, 94, 1216-1225.	1.6	35
23	The Impact of Î”G on the Oral Bioavailability of Low Bioavailable Therapeutic Agents. Journal of Pharmacology and Experimental Therapeutics, 2005, 312, 199-205.	1.3	45
24	Multidrug Resistance and Anticonvulsants: New Studies with Some Enaminones. Current Medicinal Chemistry, 2004, 11, 2093-2103.	1.2	19
25	DM27, an enaminone, modifies thein vitro transport of antiviral therapeutic agents. Biopharmaceutics and Drug Disposition, 2004, 25, 227-236.	1.1	35
26	The effect of Î”G on the transport and oral absorption of macromolecules. Journal of Pharmaceutical Sciences, 2004, 93, 1310-1319.	1.6	36
27	The influence of enaminones on the transport and oral bioavailability of P-glycoprotein substrate therapeutic agents. International Journal of Pharmaceutics, 2004, 273, 135-147.	2.6	10
28	Preclinical evaluation of the pharmacokinetics, brain uptake and metabolism of E121, an antiepileptic enaminone ester, in rats. Biopharmaceutics and Drug Disposition, 2003, 24, 397-407.	1.1	14
29	Synthesis and anticonvulsant activity of enaminones Part 7. Synthesis and anticonvulsant evaluation of ethyl 4-[(substituted phenyl)amino]-6-methyl-2-oxocyclohex-3-ene-1-carboxylates and their corresponding 5-methylcyclohex-2-enone derivatives. European Journal of Medicinal Chemistry, 2003, 38, 49-64.	2.6	79
30	Effect of the biologically active fragment of zonula occludens toxin, Î”G, on the intestinal paracellular transport and oral absorption of mannitol. International Journal of Pharmaceutics, 2003, 251, 113-121.	2.6	40
31	Enhanced permeability of molecular weight markers and poorly bioavailable compounds across Caco-2 cell monolayers using the absorption enhancer, zonula occludens toxin. Pharmaceutical Research, 2002, 19, 1680-1688.	1.7	52